Literature DB >> 24679390

Do the dissociative side effects of ketamine mediate its antidepressant effects?

David A Luckenbaugh1, Mark J Niciu1, Dawn F Ionescu1, Neal M Nolan1, Erica M Richards1, Nancy E Brutsche1, Sara Guevara1, Carlos A Zarate2.   

Abstract

BACKGROUND: The N-methyl-d-aspartate receptor antagonist ketamine has rapid antidepressant effects in major depression. Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy.
METHODS: Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder and bipolar disorder who received a single subanesthetic ketamine infusion were analyzed. Pearson correlations were performed to examine potential associations between rapid changes in dissociation and psychotomimesis with the Clinician-Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale (BPRS), respectively, manic symptoms with Young Mania Rating Scale (YMRS), and vital sign changes, with percent change in the 17-item Hamilton Depression Rating scale (HDRS) at 40 and 230min and Days 1 and 7.
RESULTS: Pearson correlations showed significant association between increased CADSS score at 40min and percent improvement with ketamine in HDRS at 230min (r=-0.35, p=0.007) and Day 7 (r=-0.41, p=0.01). Changes in YMRS or BPRS Positive Symptom score at 40min were not significantly correlated with percent HDRS improvement at any time point with ketamine. Changes in systolic blood pressure, diastolic blood pressure, and pulse were also not significantly related to HDRS change. LIMITATIONS: Secondary data analysis, combined diagnostic groups, potential unblinding.
CONCLUSIONS: Among the examined mediators of ketamine׳s antidepressant response, only dissociative side effects predicted a more robust and sustained antidepressant. Prospective, mechanistic investigations are critically needed to understand why intra-infusion dissociation correlates with a more robust antidepressant efficacy of ketamine. Published by Elsevier B.V.

Entities:  

Keywords:  Bipolar depression; Blood pressure; Ketamine; Major depressive disorder; Predictors; Psychotomimetic

Mesh:

Substances:

Year:  2014        PMID: 24679390      PMCID: PMC4065787          DOI: 10.1016/j.jad.2014.02.017

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  33 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

Authors:  J D Bremner; J H Krystal; F W Putnam; S M Southwick; C Marmar; D S Charney; C M Mazure
Journal:  J Trauma Stress       Date:  1998-01

3.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

4.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

Authors:  A Breier; C M Adler; N Weisenfeld; T P Su; I Elman; L Picken; A K Malhotra; D Pickar
Journal:  Synapse       Date:  1998-06       Impact factor: 2.562

5.  Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Authors:  Sargo Aalto; Jouni Ihalainen; Jussi Hirvonen; Jaana Kajander; Harry Scheinin; Heikki Tanila; Kjell Någren; Harry Vilkman; Lars L Gustafsson; Erkka Syvälahti; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

7.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

8.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

9.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  91 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

3.  KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.

Authors:  David R Patterson; Christine Hoffer; Mark P Jensen; Shelley A Wiechman; Sam R Sharar
Journal:  Int J Clin Exp Hypn       Date:  2018 Jul-Sep

Review 4.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 5.  Ketamine enantiomers in the rapid and sustained antidepressant effects.

Authors:  John Muller; Sahana Pentyala; James Dilger; Srinivas Pentyala
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

6.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

7.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

Review 8.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

9.  Current Trends in Identifying Rapidly Acting Treatments for Depression.

Authors:  Dawn F Ionescu; George I Papakostas
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-15

10.  Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.

Authors:  Elia E Acevedo-Diaz; Grace W Cavanaugh; Dede Greenstein; Christoph Kraus; Bashkim Kadriu; Lawrence Park; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2020-07-30       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.